37 related articles for article (PubMed ID: 33788752)
1. High-grade serous ovarian carcinoma with a sertoliform pattern associated with BRCA mutation: a clinicopathological and molecular analysis.
Travaglino A; Santoro A; Arciuolo D; Raffone A; Scaglione G; D'Alessandris N; Valente M; Sfregola S; Fulgione C; Onori ME; Minucci A; Zannoni GF
Virchows Arch; 2023 Dec; 483(6):879-883. PubMed ID: 37166561
[TBL] [Abstract][Full Text] [Related]
2. A Clinical and Immunopathological Analysis of Carcinoma of the Ovary with an Emphasis on Post-chemotherapy Histopathologic Changes.
Rubina H; Ratnagiri R; Uppin MS; Ayesha S; Lakshmi K M; Chowdary SB; Uppin SG
Indian J Surg Oncol; 2023 Sep; 14(3):545-552. PubMed ID: 37900629
[TBL] [Abstract][Full Text] [Related]
3. Management of retroperitoneal high-grade serous carcinoma of unknown origin: A case report.
Hsieh WL; Ding DC
World J Clin Cases; 2024 Feb; 12(6):1190-1195. PubMed ID: 38464925
[TBL] [Abstract][Full Text] [Related]
4. Case report: Metastatic ovarian mucinous carcinoma to the breast: diagnostic challenges and pitfalls.
Laokulrath N; Lim SK; Lim HY; Gudi M; Tan PH
Front Oncol; 2024; 14():1364011. PubMed ID: 38562166
[TBL] [Abstract][Full Text] [Related]
5. Opening the black box: spatial transcriptomics and the relevance of AI-detected prognostic regions in high grade serous carcinoma.
Laury AR; Zheng S; Aho N; Fallegger R; Hänninen S; Saez-Rodriguez J; Tanevski J; Youssef O; Tang J; Carpén OM
Mod Pathol; 2024 May; ():100508. PubMed ID: 38704029
[TBL] [Abstract][Full Text] [Related]
6. Mesonephric-like Carcinosarcoma of the Uterine Corpus: Clinicopathological, Molecular and Prognostic Characteristics in Comparison With Uterine Mesonephric-like Adenocarcinoma and Conventional Endometrial Carcinosarcoma.
Park S; Park E; Kim HS
Cancer Genomics Proteomics; 2022; 19(6):747-760. PubMed ID: 36316041
[TBL] [Abstract][Full Text] [Related]
7. Endometrioid Carcinomas of the Ovaries and Endometrium Involving Endocervical Polyps: Comprehensive Clinicopathological Analyses.
Sohn J; Lee Y; Kim HS
Diagnostics (Basel); 2022 Sep; 12(10):. PubMed ID: 36292027
[TBL] [Abstract][Full Text] [Related]
8. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Analyses of Clinicopathological, Molecular, and Prognostic Characteristics With Retrospective Review of 237 Endometrial Carcinoma Cases.
Kim HG; Kim H; Yeo MK; Won KY; Kim YS; Han GH; Kim HS; Na K
Cancer Genomics Proteomics; 2022; 19(4):526-539. PubMed ID: 35732320
[TBL] [Abstract][Full Text] [Related]
9. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Immunohistochemical Analyses Using Markers for Mesonephric, Endometrioid and Serous Tumors.
Kim H; Na K; Bae GE; Kim HS
Diagnostics (Basel); 2021 Nov; 11(11):. PubMed ID: 34829389
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Mesonephric-like Adenocarcinoma With Multifocal Microscopic Involvement of the Fimbrial Surface: Potential for Misdiagnosis of Tubal Intraepithelial Metastasis as Serous Tubal Intraepithelial Carcinoma Associated With Ovarian High-grade Serous Carcinoma.
Kim H; Bae GE; Jung YY; Kim HS
In Vivo; 2021; 35(6):3613-3622. PubMed ID: 34697203
[TBL] [Abstract][Full Text] [Related]
11. Mesonephric-like Differentiation of Endometrial Endometrioid Carcinoma: Clinicopathological and Molecular Characteristics Distinct from Those of Uterine Mesonephric-like Adenocarcinoma.
Park S; Bae GE; Kim J; Kim HS
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441384
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
[TBL] [Abstract][Full Text] [Related]
13. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
[TBL] [Abstract][Full Text] [Related]
14. A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy.
Casey L; Köbel M; Ganesan R; Tam S; Prasad R; Böhm S; Lockley M; Jeyarajah AJ; Brockbank E; Faruqi A; Gilks CB; Singh N
Histopathology; 2017 Nov; 71(5):736-742. PubMed ID: 28570008
[TBL] [Abstract][Full Text] [Related]
15. Ovarian High-Grade Serous Carcinoma: Assessing Pathology for Site of Origin, Staging and Post-neoadjuvant Chemotherapy Changes.
Casey L; Singh N
Surg Pathol Clin; 2019 Jun; 12(2):515-528. PubMed ID: 31097113
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW; Riopel MA; Smith Sehdev AE; Ronnett BM; Kurman RJ
Am J Surg Pathol; 2002 Dec; 26(12):1529-41. PubMed ID: 12459620
[TBL] [Abstract][Full Text] [Related]
17. Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.
Kwon HJ; Song SY; Kim HS
Anticancer Res; 2021 Mar; 41(3):1579-1586. PubMed ID: 33788752
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
